text
"['\n4. 매출 및 수주상황\n가. 연결기준\n(단위: 백만원)\n구분\n2023년 3분기\n2022년\n2021년\n사업부문\n품목\n국내\n해외\n합계\n국내\n해외\n합계\n국내\n해외\n합계\n의약품 제조 및 판매\n혈액제제류\n233,542\n114,801\n348,343\n329,493\n136,636\n466,129\n312,885\n132,967\n445,852\nOTC류\n87,886\n274\n88,160\n141,953\n513\n142,466\n174,174\n237\n174,411\n일반제제류\n270,043\n24,706\n294,749\n325,556\n52,190\n377,746\n283,655\n32,546\n316,201\n백신제제\n130,203\n95,515\n225,718\n137,902\n118,518\n256,420\n155,939\n107,229\n263,168\n기타\n163,628\n10,979\n174,607\n259,590\n27,849\n287,439\n210,773\n37,062\n247,835\n검체 등 진단 및 분석\n150,306\n9,194\n159,500\n248,207\n16,167\n264,374\n187,367\n-\n187,367\n의료 서비스 및 시스템 개발공급\n139,773\n-\n139,773\n166,042\n-\n166,042\n141,569\n-\n141,569\n임대 및 서비스업\n46,743\n-\n46,743\n66,770\n-\n66,770\n73,934\n-\n73,934\n기타\n143,054\n11,660\n154,714\n191,561\n17,414\n208,975\n151,719\n4,332\n156,051\n보고부문 합계\n1,365,178\n267,129\n1,632,307\n1,867,074\n369,287\n2,236,361\n1,692,015\n314,373\n2,006,388\n연결조정 등\n-\n-\n(115,938)\n-\n-\n(156,801)\n-\n-\n(165,829)\n연결재무제표 금액\n-\n-\n1,516,369\n-\n-\n2,079,560\n-\n-\n1,840,559\n나. 별도기준\n(단위 : 백만원)\n\xa0 \xa0 \xa0 \xa0 \xa0구 \xa0분\n2023년 3분기\n2022년\n2021년\n영업수익:\n임대료수익\n10,002\n15,003\n14,712\n배당금수익\n19,356\n23,675\n32,779\n기타영업수익\n17,385\n28,092\n26,443\n합계\n46,743\n66,770\n73,934\n다. 수주상황\n(단위 : 백만원)\n품목\n수주일자\n납기\n수주총액\n기납품액\n수주잔고\n수량\n금액\n수량\n금액\n수량\n금액\n-\n-\n-\n-\n-\n-\n-\n-\n-\n합 계\n-\n-\n-\n-\n-\n-\n']"
